Latest Intellectual Property News

Argent BioPharma has signed a binding agreement to acquire AusCann’s 48% stake in CannPal, enhancing its clinical and intellectual property assets for CannEpil®. The deal includes an option for the Neuvis® drug-delivery platform and aligns with Argent’s U.S. dual-listing ambitions.

Neometals and Mineral Resources’ joint venture Reed Advanced Materials has teamed up with electrochemical leader De Nora to pilot an integrated lithium hydroxide production plant, advancing sustainable battery materials technology.

Zeotech Limited is set to validate its zeolite-based methane biofilter in a six-month on-site trial at a North Burnett landfill, aiming to curb emissions by over 90%. This marks a critical step from lab success to real-world application, supporting Australia’s climate goals.

Electro Optic Systems (EOS) has acquired European defence tech firm MARSS, integrating advanced AI-enabled command and control systems to create a comprehensive counter-drone solution. This strategic move positions EOS as a prime contractor for larger defence programs and expands its global footprint.

Aristocrat Leisure and Light & Wonder have resolved their high-profile intellectual property litigation with a $190 million settlement and the withdrawal of disputed games from the market.

Aristocrat Leisure and Light & Wonder have resolved a high-profile intellectual property dispute with a $190 million settlement and the withdrawal of contested games worldwide.

Mesoblast Limited reports a 60% jump in Ryoncil sales for the December quarter, underpinned by a new $125 million financing facility that strengthens its balance sheet and strategic flexibility.

CurveBeam AI has received official Chinese regulatory approval for a strategic $10 million investment from WEGO Orthopaedics, marking a major step in its expansion into Greater China. The initial $4 million tranche at a premium share price is expected imminently, underpinning a decade-long commercialisation deal.

Island Pharmaceuticals has been granted a key US patent for Galidesivir, extending intellectual property protection through 2031 for treating filoviridae viruses including Marburg and Ebola. This milestone aligns with the company’s clinical development strategy and recent FDA regulatory progress.

Mesoblast has refinanced its senior debt with a new US$125 million, five-year credit facility that lowers borrowing costs and preserves key assets, positioning the company for strategic growth.

Aeeris Ltd has received a $506,992.50 refundable R&D tax incentive for FY25, fueling advancements in its proprietary Australian Weather And Risk Environment (AWARE) system and AI-driven forecasting tools.

Weebit Nano has raised its FY26 revenue guidance to a minimum of $10 million following the signing of multiple IP licensing agreements with semiconductor fabs and product companies.